Clinical Trial Detail

NCT ID NCT03455829
Title G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors G1 Therapeutics, Inc.
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

G1T38 + Osimertinib

Age Groups: senior adult

No variant requirements are available.